Scalper1 News
Salix Pharmaceuticals’ (SLXP) stock climbed above Valeant Pharmaceuticals’ richer offer of $173 per share, suggesting investors expect another counterbid from Endo International. The new terms also include a $100 million increase in the break-up fee to about $450 million. And if the conditions for the offer have not been met by April 8, the offer will drop back to the original $158-per-share price. Salix shares were up 2.7% to nearly 174 in Scalper1 News
Scalper1 News